Summary
This 8-K filing from Merck & Co., Inc. (MRK), filed on September 19, 2008, pertains to actions taken by the Compensation Committee of Schering-Plough's Board of Directors regarding the compensation of Dr. Thomas P. Koestler, Executive Vice President & President of Schering-Plough Research Institute. The report details adjustments to Dr. Koestler's base salary, annual incentive target, and a special stock award, effective in late 2008 and early 2009. These compensation changes are explicitly linked to Dr. Koestler's strong performance in a critical research and development role and the competitive landscape for executive talent. The stock award, in particular, includes a multi-year vesting period tied to research and development initiatives and continued employment, emphasizing retention and long-term commitment to the company's strategic goals. Investors should note that these actions are specific to Schering-Plough and its executive compensation, which, at the time of this filing, would be relevant in the context of any ongoing or potential business interactions or mergers between Merck and Schering-Plough.
Key Highlights
- 1Schering-Plough's Compensation Committee adjusted compensation for Dr. Thomas P. Koestler, EVP & President of Research Institute.
- 2Effective October 1, 2008, Dr. Koestler's base salary increased by 5% to $864,000.
- 3Effective January 1, 2009, his target annual incentive increased from 70% to 80% of base salary.
- 4A special service- and performance-based stock award of 250,000 Schering-Plough common shares was granted on October 1, 2008.
- 5The stock award is subject to R&D initiative performance and a four-year retention requirement (until October 1, 2012).
- 6These actions are a recognition of Dr. Koestler's strong performance and retention strategy amidst competition for executive talent.
- 7All other terms of Dr. Koestler's December 19, 2006 employment agreement remain unchanged.